Craniosacral Therapy/Upledger

Systematic reviews consistently find no evidence of clinical benefit beyond placebo. No high-quality positive RCTs.

Applicable to chronic pain, headache, TMJ, and pediatric populations; limited by evidence concerns.

Very limited to no third-party coverage; self-pay; HSA eligible in some cases.

4-8 day introductory course; multiple levels required for full certification; significant cumulative cost.

Low employer demand in evidence-based clinical settings; primarily private practice and integrative wellness.

Some patients report subjective benefit, consistent with placebo response.

Predominantly cash-pay wellness clientele, particularly in peds and chronic pain niches.

Allows premium session pricing in wellness markets.

Distinctive but controversial; differentiates among holistic clientele.

Highly practitioner-dependent style; hard to scale across staff.

Steady niche demand in wellness/peds communities but not mainstream.

Multi-level Upledger curriculum is lengthy and expensive.

Viewed skeptically in academic PT/OT; can be a liability for credibility.

Minimal credible scholarship; most published work is from advocates.

Not part of mainstream curricula; conflicts with evidence-based teaching.

Evidence is weak; systematic reviews are generally negative or inconclusive.

Not listed in faculty postings.

Significant time/cost with little to no academic return.